OPADE: Optimise and predict antidepressant efficacy for people with major depressive disorders using multi-omics analysis


Need – 280M of people worldwide suffer from major depressive disorders (MDD). Although there is a well populated therapeutic landscape of anti-depressants, the number of patients in remission is particularly low with not more than 6% of the patients who fully benefit from the current therapeutic journey. 


OPADE’s objective is to identify key biomarkers that support the decision-making process of the healthcare providers through the development and commercialisation of an AI (artificial intelligence) / ML (machine learning) -predictive tool.


The project focuses on the gut–brain-axis which plays a major role in MDD. Through clinical

investigations, the consortium partners will study the combination between genetics, epigenetics,

microbiome and inflammatory networks to:

  • Establish patient profiles to predict & optimise the efficacy of the antidepressants prescribed
  • with an increase in the remission rate and reduction of impairment of real-life functioning,
  • Establish the possible correlation between neuroinflammatory indices, target indicators of the
  • microbiome, metabolomics, immune-profile linked, epigenomic, enzymatic algorithms
  • Evaluate molecular and non-molecular biomarkers that may represent predictive indices of
  • recurrence
  • Improve the diagnostic accuracy for primary prevention
  • Evaluate retrospectively, using accurate anamnesis, the onset of depressive symptoms in
  • adolescence
  • Establish how much and to what extent blood biomarkers correlate with other specific
  • biomarkers

OPADE Consortium: